Investigating lipid mediators to protect the brain after a stroke
Official title: Neuroprotective lipid mediators target penumbra in experimental ischemic stroke
Funded at Lsu Health Sciences Center · NIH-10941655 · Data updated 2026-11-12
This study is looking at how special fats called elovanoids can help protect brain cells and improve recovery after a stroke, and it's designed for people who want to learn about new ways to support brain health after such an event.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lsu Health Sciences Center NIH-funded |
| Lab location | 1 site (New Orleans, United States) |
| Project start | July 5, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $481,617 |
| NIH project number | 1R01NS138259-01 |
| Project ID | NIH-10941655 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have experienced an ischemic stroke and are seeking innovative treatment options.
✕Less likely to help
Patients who have not had a stroke or those with hemorrhagic stroke may not benefit from this research.
What this research studies
This research focuses on the use of elovanoids, which are specialized lipid molecules derived from fatty acids, to protect brain cells in the area surrounding a stroke. The study aims to understand how these elovanoids can promote cell survival and restore brain function after ischemic stroke by targeting specific genes in brain cells. Researchers will use advanced techniques, including MRI and gene sequencing, to assess the effects of these lipid mediators on brain health in a rat model of stroke. The ultimate goal is to develop a new therapeutic approach that enhances recovery and reduces disability after a stroke.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve recovery outcomes for stroke patients.
How similar studies have gone: Previous research has shown promising results with similar lipid-based approaches in animal models, indicating potential for success in this novel application.
Where this research is happening
-
Lsu Health Sciences Center
New Orleans, United States Active
Researchers
- Principal investigator: Bazan, Nicolas G. — Lsu Health Sciences Center
- Study coordinator: Bazan, Nicolas G.
Related research
Other NIH-funded projects on the same topics.
-
Improving blood flow after stroke by breaking down NETs
Aims to see if breaking down neutrophil extracellular traps (NETs) after an ischemic stroke can improve blood flow and reduce brain injury in patients.
-
EP2 blockers to protect the brain after a stroke
Aims to test brain-permeable EP2 antagonists to reduce damage after ischemic stroke and improve recovery.
-
Genetic testing to find causes of early-onset ischemic stroke
This project uses whole-exome sequencing to look for gene changes that may cause ischemic stroke in adults who had a stroke at a young age.
-
Targeted nanomedicine to protect the brain after stroke
A targeted drug-delivery approach aims to boost blood-brain barrier repair and reduce brain damage after an acute ischemic stroke in patients at risk.
-
How biological aging and blood proteins relate to thinking after a stroke
This project looks at whether measures of biological aging and patterns of blood proteins help explain which stroke survivors keep their thinking sharp and which go on to develop vascular dementia.
-
Repurposing NEXLETOL to treat ischemic stroke
Aims to see if the cholesterol drug NEXLETOL can help people after an ischemic stroke by supporting brain energy use and reducing injury.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.